Kilitch Drugs (India) Ltd

Kilitch Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kilitch Drugs (India) Ltd

₹ 349 -0.33%
16 Apr 12:18 p.m.
kilitch.com BSE: 524500 NSE : KILITCH
About

Kilitch Drugs (India) Ltd is a speciality pharmaceutical company engaged in manufacturing and trading of pharmaceutical products in domestic and international markets.[1]

Key Points

Product Portfolio
The company's product portfolio includes parenteral and nasal products, oral formulations, effervescent tablets & powders, medical devices, nutritional products, cosmetics & herbal products & others. Besides this, it has 400+ products registered across the world. [1] [2]

Website BSE NSE
  • Market Cap ₹ 561 Cr.
  • Current Price ₹ 349
  • High / Low ₹ 470 / 157
  • Stock P/E 29.4
  • Book Value ₹ 132
  • Dividend Yield 0.00 %
  • ROCE 9.54 %
  • ROE 8.10 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 23.1% CAGR over last 5 years

Cons

  • Stock is trading at 2.64 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 5.80% over last 3 years.
  • Company has high debtors of 165 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
20.32 21.14 19.51 23.05 30.56 32.03 23.57 22.43 28.50 43.28 31.12 31.57 29.77
17.19 20.70 17.07 21.01 28.01 28.05 20.44 19.28 24.28 36.59 25.88 25.73 25.76
Operating Profit 3.13 0.44 2.44 2.04 2.55 3.98 3.13 3.15 4.22 6.69 5.24 5.84 4.01
OPM % 15.40% 2.08% 12.51% 8.85% 8.34% 12.43% 13.28% 14.04% 14.81% 15.46% 16.84% 18.50% 13.47%
0.99 1.34 1.48 0.59 1.72 0.77 1.39 0.66 1.11 1.43 0.98 0.92 3.40
Interest 0.12 0.16 0.13 0.12 0.24 0.18 0.07 0.23 0.28 0.41 0.38 0.55 0.53
Depreciation 0.29 0.29 0.23 0.23 0.24 0.26 0.27 0.31 0.38 0.37 0.26 0.28 0.30
Profit before tax 3.71 1.33 3.56 2.28 3.79 4.31 4.18 3.27 4.67 7.34 5.58 5.93 6.58
Tax % 15.90% 35.34% 18.54% 18.42% 27.18% 29.93% 27.75% -11.93% 16.06% 30.11% 25.09% 28.50% 16.41%
3.12 0.86 2.89 1.85 2.77 3.02 3.01 3.64 3.93 5.13 4.19 4.24 5.50
EPS in Rs 2.01 0.56 1.86 1.19 1.78 1.94 1.93 2.34 2.52 3.29 2.69 2.64 3.42
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
107 33 15 19 21 27 50 96 61 70 105 118 136
200 37 19 21 24 27 44 79 59 65 94 100 114
Operating Profit -93 -4 -4 -2 -3 -0 6 17 2 5 11 17 22
OPM % -87% -11% -25% -9% -15% -0% 12% 18% 3% 8% 11% 15% 16%
200 8 6 3 2 1 3 4 6 4 5 5 7
Interest 3 0 0 0 0 0 0 1 1 1 1 1 2
Depreciation 5 1 1 2 2 1 1 1 1 1 1 1 1
Profit before tax 99 3 1 -1 -2 -0 7 20 5 8 14 19 25
Tax % 21% -0% -10% 79% 18% 91% 13% 24% 15% 18% 24% 19%
78 3 1 -0 -2 -0 6 15 4 6 11 16 19
EPS in Rs 58.91 2.48 0.89 -0.14 -1.55 -0.03 4.52 9.62 2.89 3.98 6.76 10.09 12.04
Dividend Payout % 51% 0% 0% 0% 0% 0% 11% 5% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 14%
5 Years: 19%
3 Years: 25%
TTM: 27%
Compounded Profit Growth
10 Years: 15%
5 Years: 23%
3 Years: 73%
TTM: 40%
Stock Price CAGR
10 Years: 33%
5 Years: 11%
3 Years: 50%
1 Year: 111%
Return on Equity
10 Years: 3%
5 Years: 6%
3 Years: 6%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 13 13 13 13 13 13 14 15 15 15 16 16 16
Reserves 103 106 107 107 105 106 115 136 136 147 162 175 196
1 0 0 0 0 1 1 9 13 15 20 22 28
61 18 9 7 8 10 16 12 10 18 34 40 29
Total Liabilities 178 137 129 127 126 130 145 172 174 196 232 252 269
8 9 9 9 8 8 7 8 8 7 14 15 15
CWIP 0 0 0 0 0 0 0 0 0 0 0 1 2
Investments 140 109 40 72 92 96 101 100 98 106 117 110 114
29 19 79 46 25 26 37 65 68 82 101 126 139
Total Assets 178 137 129 127 126 130 145 172 174 196 232 252 269

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-29 2 -31 -8 18 1 -1 7 7 6 5 6
43 37 72 -31 -20 -1 -2 -22 -10 -5 -16 6
-11 -47 -0 -0 -0 -0 6 15 1 2 8 3
Net Cash Flow 2 -9 41 -39 -2 -0 2 0 -1 3 -3 15

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 49 136 213 243 285 200 150 88 102 120 144 165
Inventory Days 10 21 162 124 110 84 39 33 57 34 30 13
Days Payable 24 183 292 123 152 183 108 38 81 127 168 180
Cash Conversion Cycle 35 -26 83 244 243 101 82 83 78 27 6 -3
Working Capital Days -148 -29 102 196 231 130 104 78 96 62 50 71
ROCE % 8% 3% -2% -1% -2% -0% 5% 12% 3% 4% 7% 10%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
68.33% 68.33% 68.25% 68.25% 68.25% 68.24% 68.24% 68.24% 68.24% 69.23% 69.23% 69.23%
0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
31.67% 31.67% 31.73% 31.75% 31.75% 31.75% 31.75% 31.75% 31.76% 30.78% 30.76% 30.77%
No. of Shareholders 9,2148,7409,1299,1339,2099,3809,4359,5229,5739,0029,0629,525

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls